微信小陈
微信小章| 产品名称： | U-118 MG |
|---|---|
| 商品货号： | TS210723 |
| Organism： | Homo sapiens, human |
| Tissue： | brain |
| Cell Type： | Glioblastoma |
| Product Format： | frozen |
| Morphology： | mixed |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | classified as grade IV as of 2007, glioblastoma; astrocytoma |
| Age： | 50 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | U-118 MG and U-138 MG are very similar cytogenetically and share at least six derivative marker chromosomes.
This is one of a number of cell lines derived from malignant gliomas (see also ATCC HTB-14 and ATCC HTB-16) by J. Ponten and associates from 1966 to 1969. |
| Clinical Data： | 50 years Caucasian male |
| Antigen Expression： | Blood Type A, Rh+; HLA Aw24, A28, B12, Bw47 |
| Tumorigenic： | Yes |
| Effects： | Yes, in nude mice inoculated subcutaneously with 10(7) cells (Tumors developed within 21 days at 100% frequency (5/5).) |
| Comments： | NOTE: The two glioblastoma cell lines, U-118 MG (HTB-15) and U-138 MG (HTB-16), reportedly from different individuals have identical VNTR and similar STR patterns.
U-118 MG and U-138 MG are very similar cytogenetically and share at least six derivative marker chromosomes.
Mycoplasma contamination was eliminated in 1987 by treatment with BM-Cycline over a six week culture period. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week |
| Cryopreservation： | Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapot temperature |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 9 D16S539: 12,13 D5S818: 11 D7S820: 9 THO1: 6 TPOX: 8 vWA: 18 |
| Isoenzymes： | AK-1, 1-2 ES-D, 1 G6PD, B GLO-I, 1-2 Me-2, 1 PGM1, 2 PGM3, 2 |
| Name of Depositor： | J Ponten |
| Deposited As： | Homo sapiens |
| Year of Origin： | 1966 |
| References： | Beckman G, et al. G-6-PD and PGM phenotypes of 16 continuous human tumor cell lines. Evidence against cross-contamination and contamination by HeLa cells. Hum. Hered. 21: 238-241, 1971. PubMed: 4332744 Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871 Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 77210034 Olopade OI, et al. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res. 52: 2523-2529, 1992. PubMed: 1568221 Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol. Microbiol. Scand. 74: 465-486, 1968. PubMed: 4313504 Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212 Bluestein HG. Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 75: 3965-3969, 1978. PubMed: 279013 Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760 Tumors developed within 21 days at 100% frequency (5/5). |